Drugs |
Specialties
| Education
| Points

Hong Kong
Search
Sign In

Dermatology Search

Dermatology

Specialties

Multidisciplinary
Cardiology
Dermatology
Endocrinology
Gastroenterology
Hepatology
Infectious Diseases
Neurology
Obstetrics & Gynaecology
Oncology
Ophthalmology
Paediatrics
Psychiatry
Respirology
Rheumatology
Urology
Pharmacy

Country

China
Hong Kong
India
Indonesia
Malaysia
Myanmar
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand

Search

Account

Manage Account
Change Password
Points
Sign Out

Dermatology

Medical News
Case Studies
Clinical Review
Practice Insights
Drug Updates

Special Reports

Specialties

Multidisciplinary
Cardiology
Dermatology
Endocrinology
Gastroenterology
Hepatology
Infectious Diseases
Neurology
Obstetrics & Gynaecology
Oncology
Ophthalmology
Paediatrics
Psychiatry
Respirology
Rheumatology
Urology
Pharmacy

China
Hong Kong
India
Indonesia
Malaysia
Myanmar
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand

Drugs |
Specialties
| Education
| Points

Exclusive offer for doctors!

Register for a MIMS account and receive free medical publications worth $768 a year.

Continue with Google

OR

Already a member? Sign in

Dermatology

Home News Diseases Conferences Special Reports

Medical News
Case Studies
Clinical Review
Practice Insights
Drug Updates

Product Highlight - Dupixent

14 Jun 2022

First and Only Biologic Therapy that specifically targets IL-4 and IL-13, key drivers of persistent underlying Type 2 inflammation (including Atopic Dermatitis and Asthma)^1,2
Now locally approved for:
- Adult & adolescent (aged 12-17) patients with moderate-to-severe atopic dermatitis who are candidates for systemic therapy¹
- An add-on maintenance treatment for patients (12+ years) with inadequately controlled severe asthma with type 2 inflammation¹

References:
1. DUPIXENT Summary of Product Characteristics. May 2020.
2. Gandhi NA et al. Nature Rev Drug Disc 2016; 15: 35–50.

MAT-HK-2000318-1.0-08/2020

Wait Loading...

LOGIN TO READ FULL STORY

Editor's Recommendations

Related Diseases

Atopic Dermatitis

Dermatology

Specialties

Multidisciplinary
Cardiology
Dermatology
Endocrinology
Gastroenterology
Hepatology
Infectious Diseases
Neurology
Obstetrics & Gynaecology
Oncology
Ophthalmology
Paediatrics
Psychiatry
Respirology
Rheumatology
Urology
Pharmacy

News

Medical News
Case Studies
Clinical Review
Practice Insights
Drug Updates

Diseases

Dermatology Diseases

Conferences

Conferences Report

More Services

Drugs
Specialties
Education
Subscribe

About

MIMS Corporate
Term of Use
Privacy Policy
Feedback

Connect With MIMS

Copyright © 2024 MIMS Pte Ltd. All rights reserved.